Yupelri
Payments companies reported to CMS as associated with Yupelri. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Yupelri, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Yupelri
These are the largest totals companies reported as associated with Yupelri. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Tarun Madappa | Corpus Christi, TX | Pulmonary Disease | $114,758.34 |
| Jeffrey Wolf | Great Neck, NY | Pulmonary Disease | $81,652.72 |
| Antonio Anzueto | San Antonio, TX | Pulmonary Disease | $75,681.55 |
| Mark Pamer | Port Saint Lucie, FL | Pulmonary Disease | $74,948.16 |
| William Alleyne | Rock Hill, SC | Critical Care Medicine (Internal Medicine) | $71,010.15 |
| David Mares | Anderson, IN | Pulmonary Disease | $65,703.97 |
| Warren Botnick | Natchitoches, LA | Pulmonary Disease | $52,463.08 |
| Alexey Knyazhitskiy | Taunton, MA | Pulmonary Disease | $47,982.54 |
| Sandra Schuldheisz | Somerset, KY | $43,944.11 | |
| Lacey Matheis | Evansville, IN | Family | $41,625.99 |
Prescribed Yupelri?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.